Clinical trial
A Phase 2, Randomized, Active Comparator-Controlled, Open-Label, Adaptive Design Study to Assess the Safety and Efficacy of Intravenously-Administered SelK2 in Patients Undergoing Total Knee Arthroplasty
NCT03812328 is registered in ClinicalTrials.gov with Tetherex Pharmaceuticals Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Active Comparator-Controlled, Open-Label, Adaptive Design Study to Assess the Safety and Efficacy of Intravenously-Administered SelK2 in Patients Undergoing Total Knee Arthroplasty
- Lead sponsor
- Tetherex Pharmaceuticals Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 20, 2019
- Completion date
- November 14, 2019
- Enrollment
- 207 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.